Research information only, not medical advice. Gonadorelin is a synthetic decapeptide identical to natural gonadotropin-releasing hormone (GnRH), which stimulates the pituitary to release LH and FSH. Its branded US products — Factrel (diagnostic use) and Lutrepulse (pulsatile pump therapy) — were FDA-approved but were voluntarily withdrawn from the market for commercial reasons, not safety or efficacy. As of 2026 no FDA-approved gonadorelin product is commercially available in the US; it is used off-label, mainly via compounding pharmacies, including as a testicular-function adjunct during testosterone therapy — an off-label use with no large randomised controlled trials.
Gonadorelin at a glance
Gonadorelin's historical evidence base comes from the diagnostic and pulsatile-therapy trials that supported its former FDA approvals (Factrel for pituitary-gonadotroph function testing, Lutrepulse for pulsatile treatment of hypothalamic amenorrhoea). Those products were withdrawn from the US market in commercial decisions, not for safety reasons. Its current off-label use — preserving testicular function during testosterone replacement therapy — has not been evaluated in large randomised controlled trials; the evidence for that specific use is limited.
See how we grade evidence for the methodology behind this page.
Evidence profile
216 studies- Human trial 15 · 7%
- Review 59 · 27%
- Animal 94 · 44%
- In-vitro 25 · 12%
- Unknown 23 · 11%
The longer the green, the stronger the human evidence. For most research peptides the bar is dominated by animal and in-vitro work, which is a signal to read every claim carefully.
Regulatory status
Clinical trials
-
Hormone Therapy in Treating Patients With Advanced Prostate Cancer
-
Phase II Study of Leuprolide and Testosterone for Men With Kennedy's Disease or Other Motor Neuron Disease
-
Androgen Suppression Plus Radiation Therapy in Treating Patients With Prostate Cancer
-
Bicalutamide Compared With Observation Followed by Bicalutamide Plus Either Goserelin or Orchiectomy in Treating Patients With Prostate Cancer
-
Chemotherapy, Hormone Therapy, and Radiation Therapy in Treating Patients With Locally Advanced Prostate Cancer
-
Adjuvant Radiation Therapy Plus Hormone Therapy Compared With Radiation Therapy Alone in Treating Patients With Stage II or Stage III Prostate Cancer
-
Hormone Therapy With or Without Docetaxel And Estramustine in Treating Patients With Prostate Cancer That is Locally Advanced or At High Risk of Relapse
-
Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer
-
Triptorelin for Preserving Ovarian Function in Premenopausal Women Receiving Chemotherapy for Early-Stage Breast Cancer
-
A Phase II Study of PROSTVAC-V (Vaccinia)/TRICOM and PROSTVAC-F (Fowlpox)/TRICOM With GM-CSF in Patients With PSA Progression After Local Therapy for Prostate Cancer
-
Docetaxel, Estramustine and Short Term Androgen Withdrawal for Patients With a Rising PSA After Local Treatment
-
Hormone Therapy and Ipilimumab in Treating Patients With Advanced Prostate Cancer
-
Long Acting LHRH Versus Short Acting LHRH in the Treatment of Prostate Cancer
-
Androgen Suppression Combined With Elective Nodal and Dose Escalated Radiation Therapy
-
S0511, Goserelin and Anastrozole in Treating Men With Recurrent or Metastatic Breast Cancer
-
Study on the Role of Hormonal Treatment for Two Dosage Levels of Prostate Radiation Therapy Versus Prostate Radiation Therapy Alone
-
Effects of IAS in Men With Localized Biochemical Relapsed Prostate Cancer
-
Hormone Therapy With or Without Squalamine Lactate in Treating Patients Who Are Undergoing a Radical Prostatectomy for Locally Advanced Prostate Cancer
-
CMAB vs IMAB in Metastatic Prostate Cancer
-
FINNPROSTATE Study VII: Intermittent Versus Continuous Androgen Deprivation in Patients With Advanced Prostate Cancer
-
Casodex/Zoladex Biomarkers in Localised Prostate Cancer
-
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Three Dosage Strengths of Pulsatile GnRH
-
Prostate Adenocarcinoma TransCutaneous Hormones
-
Bevacizumab, Hormone Therapy, and Radiation Therapy in Treating Patients With Locally Advanced Prostate Cancer
-
Investigation of Early Hormonotherapy Efficacy of Prostate Cancer
-
Pulsatile GnRH in Anovulatory Infertility
-
Flexible GnRH Antagonist vs Flare up GnRH Agonist Protocol in Poor Responders
-
Comparison of the Long GnRH Agonist Protocol and the Flexible GnRH Antagonist Protocol of Ovarian Stimulation
-
Radiation Therapy With or Without Goserelin in Treating Patients Who Have Undergone Surgery for Recurrent or Refractory Prostate Cancer
-
Goserelin Acetate Study for Ovarian Function in Patients With Primary Breast Cancer
-
Immediate Versus Deferred Androgen Deprivation Therapy,Goserelin for Recurrent Prostate Cancer After Radical Radiotherapy
-
The ELDORADO (Eligard®, Docetaxel and Radiotherapy) Study
-
Pazopanib Hydrochloride After Leuprolide Acetate or Goserelin Acetate in Treating Patients With Relapsed Prostate Cancer
-
Treatment of Endometriosis With Norethindrone Acetate ( NA) VS. Gonadotropin- Releasing Hormone (GnRH) Agonist (Lupron Depot 11.25 mg)
-
A Prospective, Single-Arm Study to Evaluate the Efficacy and Safety of Zoladex 3.6mg Combined With CEF Chemotherapy as Neo-Adjuvant Therapy in Hormone Responsive, Premenopausal, Operable Breast Cancer
-
GnRH Agonist and Antagonists in an Oocyte Donation Program
-
Study of Abraxane Plus Hormonal Therapy as Initial Treatment of Unresectable or Metastatic Prostate Cancer
-
Efficacy and Safety Study of Pamoate of Triptorelin in Children With Precocious Puberty
-
Gonadotropin-releasing Hormone Antagonist on Triggering Day: A Randomized Controlled Study
-
Efficacy Study of Methylphenidate Hydrochloride to Reduce Fatigue in Prostate Cancer Patients Receiving Hormone Therapy
-
Testosterone and Lipolysis, Insulin Sensitivity and Protein Metabolism
-
Brain Function in Premenopausal Women Receiving Tamoxifen With or Without Ovarian Function Suppression for Early-Stage Breast Cancer on Clinical Trial IBCSG 24-02
-
Human Menopausal Gonadotropin (HMG) vs Recombinant Follicle Stimulating Hormone (rFSH) in Gonadotropin Releasing Hormone (GnRH) Antagonist Cycles
-
Prevention of Obesity in Women Via Estradiol Regulation
- NCT00702234 COMPLETED
Pregnancy and Neonatal Follow-up of Ongoing Pregnancies Established in Clinical Trial P05714 (Care Program)(P05715)
-
PGL4001 Versus GnRH-agonist in Uterine Myomas
-
Novel MRI Strategies as a Non-invasive Biomarker in Women With Uterine Fibroids
-
Goserelin, Flutamine, and Radiation Therapy in Treating Patients With Locally Advanced Prostate Cancer
-
Study of Effectiveness of IMC-A12 Antibody Combined With Hormone Therapy Prior to Surgery to Treat Prostate Cancer
-
A 4 Year Combination Therapy of Growth Hormone and (GnRH) Agonist in Children With a Short Predicted Height
-
Investigation of the Effect of Degarelix in Terms of Prostate Volume Reduction in Prostate Cancer Patients
-
Effects of Triptorelin Pamoate in Children With Precocious Puberty - Follow up Study
-
Kisspeptin Administration in the Adult
-
Everolimus, Bicalutamide, and Leuprolide Acetate in Treating Patients Undergoing Radiation Therapy For High-Risk Locally Advanced Prostate Cancer
-
Evaluation of the Luteolytic Effect of a Gonadotropin Releasing Hormone (GnRH) Agonist After the Administration of Human Chorionic Gonadotropin (hCG) in the Initial Follicular Phase a Its Influence on the Prognosis of in Vitro Fertilization Treatment
- NCT01081873 COMPLETED
Study to Document Treatment Patterns and to Evaluate Leuprolide and Alternative Therapeutic Approaches to the Treatments of Advanced Prostate Cancer
-
Study Comparing Orteronel Plus Prednisone in Participants With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
-
Neoadjuvant Ipilimumab in Prostate Cancer
-
A Phase I/II Trial of AEZS-108 in Urothelial Cancer Patients Who Failed Platinum-chemotherapy
- NCT01311037 UNKNOWN
The Combination of GnRh Analogue and Aromatase Inhibitor in Receptor Positive Premenopausal Women With Advanced Breast Cancer
-
Effect of GTx-758 on Total and Free Testosterone Levels in Men With Prostate Cancer
-
Preservation of Ovarian Function After Hematopoietic Cell Transplant
-
Initiation of Androgen Deprivation Therapy for Prostate Cancer Using Degarelix Followed by Leuprolide
-
EMD 525797 in Subjects With Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer
-
Ipilimumab + Androgen Depravation Therapy in Prostate Cancer
-
Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer
-
Effect of Short Term Ovarian Suppression on Androgen Overproduction in Overweight Girls With Androgen Excess
-
FASTR: Fairly Brief Androgen Suppression and Stereotactic Radiotherapy for High Risk Prostate Cancer
-
Efficacy and Safety of TAK-385 in the Treatment of Endometriosis
-
Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer
- NCT01510054 WITHDRAWN
Endometrial Luteal Phase Characteristics and Luteal Phase Support in Controlled Ovarian Stimulation Protocols With GnRH Antagonists:Focusing on MicroRNA
-
Neoadjuvant Chemohormonal Therapy Followed by Salvage Surgery for High Risk PSA
-
Relationship Between the Menstrual Cycle and Heart Disease in Women
-
Comparing Ovarian Stimulation for Assisted Reproduction With Two Different Forms of Pituitary Suppression
-
The Effect of Pre-treatment With GnRH Analogues Prior in Vitro Fertilization in Patients With Endometriosis
-
Gonadotropin-releasing Hormone Agonist Prior to Myomectomy
-
Study on Influence of Leutinizing Hormone (LH) on Oocyte Maturity
-
Gene Expression Profile After Gonadotropin Releasing Hormone (GnRH) Agonist Trigger of Oocyte Maturation
-
Efficacy Study of Switching to a Lutenizing Hormone-releasing Hormone (LHRH) Antagonist From a LHRH Agonist to Treat Progressive Castrate Resistant Prostate Cancer (CRPC)
-
The Results of Preimplantation Genetic Diagnosis and Preimplantation Genetic Screening of Embryos Obtained From GnRH-agonist Long and GnRH-antagonist Ovarian Stimulation Protocol
-
Tamoxifen +/- GnRH Analogue vs Aromatase Inhibitor + GnRH Analogue in Male Breast Cancer Patients
-
Study of Red Bull™ Sugar-Free Drink for Reduction of Fatigue in Prostate Cancer Patients Receiving LHRH Agonist Therapy
-
The Influence of Adjuvant Medical Treatment of Peritoneal Endometriosis on the Outcome of IVF. A Prospective Randomized Analysis.
-
A Neoadjuvant Study of Androgen Ablation Combined With Cyclophosphamide and GVAX Vaccine for Localized Prostate Cancer
-
Study to Evaluate the Long-Term Safety and Efficacy of Elagolix in Adults With Moderate to Severe Endometriosis-Associated Pain
-
Prevention of Ovarian Function Damage by a GnRH Analogue During Chemotherapy in Hodgkin Lymphoma Patients
-
Anastrazole Plus GnRH-agonist in the Treatment of Endometriosis Recurrence
-
Akt Inhibitor MK-2206 and Anastrozole With or Without Goserelin Acetate in Treating Patients With Stage II-III Breast Cancer
-
Radiotherapy Plus Hormone Therapy in Biochemically-relapsing Prostate Cancer Patients Following Surgery
- NCT01793077 COMPLETED
Observational, Non-interventional, Non Comparative Real Life Data Collection of Depo-Eligard® 7.5 mg, 22.5 mg and 45 mg in Male Prostate Cancer Patients
-
Early Compared With Delayed Hormone Therapy in Treating Patients With Nonmetastatic Prostate Cancer
-
Phase 3 Trial to Evaluate the Efficacy and Safety of COL-1620 Vaginal Progesterone Gel
-
Effects of Dietary Omega-3 Fatty Acids on Reproductive Hormones in Obese Women
-
A Study in Patients With Metastatic Prostate Cancer to Assess How the Drug Eligard®, Affects Certain Markers in Blood and Urine, Which Are Indicators for the Disease
- NCT01942369 COMPLETED
A Study to Describe the Efficacy of Diphereline Following Conservative Surgery in Deep Infiltrating Endometriosis (DIE) Patients Over a Period of 24 Months
-
A Phase III of Cabazitaxel and Pelvic Radiotherapy in Localized Prostate Cancer and High-risk Features of Relapse
-
Efficacy Study Evaluating Chemotherapy in Prostate Cancer
-
TRial on the Endocrine Activity of Neoadjuvant Degarelix
-
Dual Trigger to Reduce Ovarian Hyperstimulation Syndrome
-
Ovulation Trigger With hCG Compared to GnRH Agonist in Patients With Repeated IVF Failures
-
A Study of Dovitinib With Androgen Deprivation Therapy (ADT) in Patients With Metastatic Prostate Cancer Receiving Primary ADT
-
T-Cell Responses to Neoantigens Post Treatment With Ipilimumab in Men With Metastatic Castration-Resistant Prostate Cancer
-
The Effect of GnRH Agonist Administered in the Luteal Phase on ART Cycle Outcomes
-
Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic
-
GnRH Agonist Triggering Supplemented With Hcg in Women With Poor Ovarian Response
-
Bay98-7196, Dose Finding / POC Study
-
Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer
-
Everolimus trIal for Advanced prememopausaL Breast Cancer Patients
-
Dual Trigger Versus GnRHa Trigger Combined With Luteal HCG Administration
-
Comparative Study Between Minidose Long Protocol and Microdose Flare Protocol in Controlled Ovarian Hyperstimulation
-
Study of GnRH-A [Leuprorelin(Lorelin Depot] Plus Leterozole +/- Everolimus for Premenopausal Women With Metastatic Breast Cancer
-
Ulipristal Acetate for the Preoperative Management of Hypoechoic Cellular Leiomyomas
- NCT02366494 COMPLETED
Micro RNAs to Predict Response to Androgen Deprivation Therapy
-
Dose Finding Study of BKM 120 in Combination With LH-RH Agonists and Bicalutamide in Men With Non Castrate Metastatic Prostate Cancer
-
A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC
-
Biosimilar Versus Urinary Gonadotropins
-
Trial of Radiotherapy With Leuprolide and Enzalutamide in High Risk Prostate Cancer
-
Effects of GnRHa on Ovarian Function Against Chemotherapy-induced-gonadotoxicity
-
MENOPUR® in a Gonadotropin-Releasing Hormone (GnRH) Antagonist Cycle With Single-Blastocyst Transfer in a High Responder Subject Population
-
Androgen Suppression With Stereotactic Body or External Beam Radiation Therapy (ASSERT)
-
Phase I Study of Combination of Gedatolisib With Palbociclib and Faslodex in Patients With ER+/HER2- Breast Cancer
- NCT02630641 COMPLETED
Perception of Cohesion Within a Relationship (Dyadic Adjustment) on the Quality of Life of Patients With Prostate Cancer With Gonadotropin-releasing Hormone.
-
Effectiveness and Safety Study of Fixed Versus Flexible of Gonadotropin-releasing Hormone Antagonist Protocol
-
Reprometabolic Syndrome Mediates Subfertility in Obesity
-
A Phase 3 Study to Evaluate the Efficacy and Safety of Relugolix (TAK-385) 40 mg Compared With Leuprorelin in the Treatment of Uterine Fibroids
- NCT02673632 UNKNOWN
The Influence of AMH on Ovarian Responsiveness to Ovulation Induction With GnRH in Women With PCOS
-
Efficacy and Safety of Medication Used to Stimulate Ovulation
-
A Study of Definitive Therapy to Treat Prostate Cancer
-
Androgen Deprivation Therapy or Androgen Deprivation Therapy Plus Definitive Treatment (Radiation or Surgery)
-
Cardiovascular Outcomes of Low Testosterone
-
AASUR in High Risk Prostate Cancer
-
Gonadotropin Releasing Hormone Antagonist in Treatment of Early-onset Severe Ovarian Hyperstimulation Syndrome
-
Darolutamide in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer
-
Co-treatment With GnRH Analogs on the Ovarian Reserve in Young Women Treated With Alkylating Agents for Cancer
-
Neoadjuvant Study of Palbociclib in Combination With Letrozole and Trastuzumab in Stage II-III ER+ HER2+ Breast Cancer
-
Triggering of Follicular Maturation
-
PalbocIclib in PreMenopausal Women With ER Positive/HER-2 Negative MetAstatic Breast Cancer
-
Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC
-
ODM-201 vs Androgen Deprivation Therapy in Hormone naïve Prostate Cancer
-
Analysis of Body Mass Index in Central Precocious Puberty Patients Treated With Leuprolide Acetate
-
Effects of SNP of GnRH Receptor Genes in IVF Patients
-
Sex-Mismatched Allogeneic Bone Marrow Transplantation for Men With Metastatic Castration-Resistant Prostate Cancer
-
Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer
-
A Study of ELIGARD® in Hormone-dependent Prostate Cancer Patients
-
Systemic Hormones and Muscle Protein Synthesis
-
Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments
-
Clinical Study of Recombinant Human Follitropin for Injection Assisted in COH Assisted IVF-ET
-
A Study to Evaluate the Safety and Efficacy of Relugolix in Men With Advanced Prostate Cancer
-
A Study to Evaluate Exemestane Tablets Combined With Ovarian Function Suppression/Ablation in Treatment of Premenopausal Breast Cancer Patients With CYP2D6*10 Mutations （STEP）
-
Hormonal Mechanisms of Sleep Restriction - Axis Study
- NCT03230994 UNKNOWN
Cooperative Adenomyosis Network
-
Study to Compare the Oestradiol Suppression, Clinical Efficacy and Safety of Two Formulations of Triptorelin (Triptorelin Pamoate PR 3-month and Triptorelin Acetate PR 1-month) in Chinese Subjects With Endometriosis
-
Menopause Effects on Vascular Function
-
Study to Compare Neoadjuvant Combination of Trastuzumab and Pertuzumab With Concurrent Taxane Chemotherapy or Endocrine Therapy and Quality of Life Assessment Under Adjuvant Therapy in Operable HER2+/HR+ Breast Cancer Patients
-
Agonist Versus Classical HCG Trigger (Poor Responders, Normoresponders and High Responders)
-
Highly Conformal, Hypofractionated, Focally Dose Escalated Post-Prostatectomy Radiotherapy
-
Neoadjuvant Endocrine Therapy in Breast Cancer
-
Multi-arm Multi-modality Therapy for Very High Risk Localized and Low Volume Metastatic Prostatic Adenocarcinoma
-
Neoadjuvant Goserelin for Triple Negative Breast Cancer
-
Fulvestrant Versus Fulvestrant Plus Palbociclib in Operable Breast Cancer Responding to Fulvestrant
-
IVM Versus Standard IVF in Infertile Patients Diagnosed With PCOS
-
Neo-adjuvant Chemotherapy With Letrozole in Patients With Estrogen Receptor Positive/HER-2 Negative Breast Cancer
- NCT03516110 COMPLETED
Health Related Quality of Life and Multidimensional Evaluations of Prostate Cancer Subjects Aged ≥ 60 Years Initiating Gonadotropin-Releasing Hormone (GNRH) Agonist Therapy
-
Phase II High Risk Prostate Cancer Trial Using Gene & Androgen Deprivation Therapies, Radiotherapy, & Surgery
-
HDR Brachytherapy, EBRT and STAD for the Treatment of Prostate Cancer
-
Density Lowering Effect of "OFS Add on to TMX"(DELFINO Trial)
-
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
-
Comparison of the Live Birth Rate Between the PPOS and the GnRH Antagonist Protocol in Patients Undergoing IVF
-
Accuracy of Ultrasound Markers Versus Biochemical Markers in Prediction of Ovarian Response in Obese Women Undergoing IVF/ICSI Treatment
-
Surgery and ART For Endometrioma
-
Recombinant FSH Investigation in the Treatment of Infertility With Assisted Reproductive Technology (ART) (RITA-2)
-
Recombinant FSH Investigation in the Treatment of Infertility With Assisted Reproductive Technology (ART) (RITA-1)
-
Follicular Fluid Sialic Acid Levels in IVF Cycles
-
A Study of Salvage Radiotherapy With or Without Enzalutamide in Recurrent Prostate Cancer Following Surgery
- NCT03867357 COMPLETED
Intramuscular Mechanisms of Androgen Deprivation-related Sarcopenia
-
Assessing the Response Rate of Neo-adjuvant Taxotere and Trastuzumab in Nigerian Women With Breast Cancer
-
PersonaLized neoAdjuvant Strategy ER Positive and HER2 Negative Breast Cancer TO Increase BCS Rate
-
FACILE: FeAsibility of First-line RiboCIclib in OLdEr Patients with Advanced Breast Cancer
-
REGN2810 Followed by Chemoimmunotherapy for Newly Metastatic Hormone-sensitive Prostate Cancer
- NCT03990194 WITHDRAWN
Real-life Study of Patients After 3-months of Leuprorelin 5mg Implant in Prostate Cancer
-
Coasting Versus Antagonist Protocol in Patients at High Risk of OHSS
-
INTREPId (INTermediate Risk Erection PreservatIon Trial)
-
Cohort Study Investigating the Association Between Antichlamydial Antibody Positivity and ART Outcomes in Women With TFI
- NCT04188275 UNKNOWN
CIRCULATING MICRO-RNA (miRNA) AND AR-V7 MUTATIONAL STATUS IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (CRPC): PRIMERA+ STUDY (PROSTATE CANCER INNOVATING MARKERS OF EXPECTED RESPONSE TO AGONIST LHRH+ ANDROGEN RECEPTOR INHIBITION
-
PREOPERATIVE GONADOTROPINE-RELEASING HORMONE AGONIST THERAPY BEFORE SURGERY FOR UTERİN FIBROIDS
-
Androgen Deprivation Therapy for Oligo-recurrent Prostate Cancer in Addition to radioTherapy
-
GnRH Therapy on Cognition in Down Syndrome
-
The LUTEAL Trial: Luteal Stimulation vs. Estrogen Priming Protocol
-
Amcenestrant (SAR439859) Plus Palbociclib as First Line Therapy for Patients With ER (+) HER2(-) Advanced Breast Cancer
-
Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study
-
Role of Suppression of Endometriosis With Progestins Before IVF-ET
-
Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial
-
Prevention of Chemotherapy-Induced Ovarian Failure With Goserelin in Premenopausal Lymphoma Patients
-
A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer
-
Effect of Education on Treatment Decision Making for Patients With Prostate Cancer on Chronic Hormone Treatments
-
Effect of GnRH Agonist vs GnRH Antagonist on Oocyte Morphology During IVF/ICSI
-
Neoadjuvant Therapy of Abiraterone Plus ADT for Intraductal Carcinoma of the Prostate
-
Freeze All on Oocyte Maturatin by Gonadotropin Agonist Versus Human Chorionic Gonadotroipin
-
Agonist Trigger With HCG Luteal Supplementation vs HCG Trigger With Progesterone Luteal Supplementation in Antagonist Controlled HyperstimulationCycle
- NCT04854707 COMPLETED
An Observational Study of Follitropin Alpha Biosimilar: the Real-world Data
-
Intramuscular Injection of Human Chorionic Gonadotropin in Frozen Embryo Transfer Cycles
-
Leuprolide Acetate 3.75 mg Depot Injection for Patients With Advanced Prostate Cancer
-
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)-China Extension
-
Androgen Deprivation, With or Without pTVG-AR, and With or Without T-Cell Checkpoint Blockade, in Patients With Newly Diagnosed, High-Risk Prostate Cancer
-
SRT Versus SRT+ADT in Prostate Cancer
-
Ovarian Hormone Regulation of Central and Cerebrovascular Hemodynamics (NoMEN Study)
-
A Study to Learn How Well Darolutamide Administered Together With Androgen Deprivation Therapy (ADT) Works in Men With Metastatic Hormone-sensitive Prostate Cancer. Results Will be Compared With ADT Alone From a Previously Conducted Study.
-
Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in Patients With PIK3CA Mutated Previously Treated HER2+ Advanced BrEasT Cancer (ALPHABET)
- NCT05087706 UNKNOWN
Exploratory Study of Molecular Profile-Associated Evidence Guided Precision Therapy for Salivary Gland Cancer（MAPS）
-
Neoadjuvant Treatment of Locally-advanced Breast Cancer Patients With Ribociclib and Letrozole
-
Enhanced Systemic Combined With Local Treatment for Primary and Metastatic Lesions in Oligo-metastatic Prostate Cancer
-
A Trial to Compare the Ovarian Response of REKOVELLE and GONAL-F in Conventional Dosing in Women Undergoing Controlled Ovarian Stimulation
-
Addition of Gonadotropin Releasing Hormone Agonist to Luteal Phase Support
- NCT05341128 COMPLETED
A Study of Medical Records From Children With Central Precocious Puberty (CPP) in China
-
Effects of Triptorelin When Given Every 6-months Under the Skin to Adult Males With Cancer in the Prostate
- NCT05567198 RECRUITING
Gonadotropin-releasing Hormone Agonist (GnRHa) in Ovarian Preservation in SLE Subjects Receiving Cyclophosphamide as Determined by Questionnaires
-
A Neoadjuvant Study of Abiraterone Acetate, Leuprolide Acetate, and Belzutifan in Men With Regional Prostate Cancer
-
Effects of Triptorelin Pamoate 6-month When Given to Adult Chinese Participants With Advanced Cancer in the Prostate
-
A Multicenter Open-label Clinical Study on the Prevention of Premature Ovarian Failure After HSCT
-
Testing the Anti-cancer Drug Darolutamide in Patients With Testosterone-Driven Salivary Gland Cancers
-
Darolutamide in Patients With Androgen Receptor-Positive Salivary Gland Carcinoma (DISCOVARY)
-
Contributions to Hypertension With Androgen Deprivation Therapy
-
Trial of Ultrahypofractionated Focal Salvage Radiotherapy for Isolated Prostate Bed Recurrence After Radical Prostatectomy
-
DPOS Versus GnRH Antagonist Protocol for Oocyte Accumulation in Low Ovarian Reserve Patients: An RCT
-
Dalpiciclib With Endocrine Therapy for Advanced Breast Cancer After CDK4/6 Inhibitor Failure (DAWNA-FES)
-
Recall by Genotype: Neuropeptide Stimulation
-
A Phase II Study of Advanced Salivary Gland Carcinoma Based on Molecular Typing
-
Effectiveness of Generic Versus Reference Cetrorelix Acetate for Ovarian Stimulation Using a Gonadotropin-releasing Hormone（GnRH）Antagonist Protocol in Women Undergoing IVF
-
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
-
Comparing the Safety and Efficacy in the Use of Hormonal Therapy on Endometriosis Patients After Conservative Surgery
-
Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer
-
Effects of Relugolix vs Leuprolide on Cardiac Function in Patients With Prostate Cancer
-
Adaptions and Resiliency to Multi-Stressor OpeRations
-
Possible Action of Resveratrol in Improving the Outcomes of IVF/ICSI in Couples With Unexplained Infertility
-
Efficacy and Safety of DKF-MA102 in Patients With Prostate Cancer
-
An Exploratory Study to Investigate the Effect of FE 999302 When Given Together With Follitropin Delta at Different Time Intervals During Controlled Ovarian Stimulation.
-
Effect of a GnRH Analog on Hepatic Steatosis
- NCT06812559 COMPLETED
Progesterone Primed Ovarian Stimulation Versus GnRH Antagonist Protocols in Women With Polycystic Ovarian Syndrome
-
The COSMYC Trial (COmbined Suppression of MYC)
-
Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer
-
Leuprolide and Goserelin for Ovarian Function Suppression in Pre- or Peri-menopausal Women With Breast Cancer, OFS Trial
-
A Short-term Preoperative, Evaluating Activity and Safety of Elacestrant Monotherapy as Compared to Elacestrant + Ovarian Function Suppression (LHRH Agonist) in Premenopausal Patients With Stage I-II ER+/HER2- Breast Cancer
-
COMPASS - COpenhagen MenoPAuSe Study
-
Comparison of IVF Outcomes Between PPOS and Antagonist Protocols in Women With PCOS
-
Estrogen to Improve Quality of Life for Men With Newly Diagnosed or Recurrent Metastatic Hormone Sensitive Prostate Cancer, EQUIP Trial
- NCT07519213 COMPLETED
Guangdong Endometriosis Retrospective Clinical Cohort
-
Successive Doses of GnRH Agonist Versus Single Dose of GnRH Agonist to Trigger Ovulation in Hyper-responders
-
RISK-ADAPT Protocol in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
-
A Study of Leuprorelin 1-Month (4-Week) Formulation in Children With Central Precocious Puberty
Indexed research
Sorted by evidence level, strongest first.
- Human trial 2026Restoring ovulation in functional hypothalamic amenorrhea: impact of polycystic ovarian morphology on hormonal response to pulsatile GnRH
This observational study found that women with functional hypothalamic amenorrhea and polycystic ovarian morphology had higher baseline AMH levels and no significant AMH increase after pulsatile GnRH therapy, unlike those without PCOM.
- Human trial 2026Protocol flexibility in PCOS: a combination of controlled ovarian stimulation and endometrial preparation strategies shows no impact on live birth outcomes after frozen embryo transfer-a retrospective cohort study
This retrospective cohort study found that in PCOS patients, live birth rates after frozen embryo transfer did not significantly differ among various combinations of controlled ovarian stimulation protocols and endometrial preparation methods.
- Human trial 2026Diagnostic performance of a simplified GnRH stimulation test in central precocious puberty: a multicentre study
This multicentre study evaluated whether shortening the GnRH stimulation test by measuring luteinizing hormone at 60 minutes maintains diagnostic accuracy for central precocious puberty in children.
- Human trial 2025Diagnostic accuracy of the triptorelin stimulation test for central precocious puberty in girls
This retrospective study evaluated the diagnostic accuracy of subcutaneous triptorelin compared to intravenous gonadorelin for diagnosing central precocious puberty in girls, finding comparable accuracy with an optimal LH peak cut-off of 7.14 IU/L at 180 minutes.
- Human trial 2025Is the triptorelin stimulation test comparable to the gonadorelin stimulation test in diagnosing central precocious puberty in boys?
This letter compares the diagnostic accuracy of triptorelin stimulation test versus gonadorelin stimulation test for central precocious puberty in boys.
- Human trial 2026Diagnostic Usefulness of Subcutaneous Triptorelin Stimulation Testing in the Evaluation of Central Precocious Puberty in Girls
This retrospective study of 662 girls with suspected central precocious puberty found that subcutaneous triptorelin stimulation testing yields similar luteinizing hormone response patterns to gonadorelin and may be a practical diagnostic alternative.
- Human trial 2026Extended Endocrine Therapy and Survival for Breast Cancer Subtypes in Premenopausal Patients
This multicenter cohort study found that extended endocrine therapy was associated with lower risks of invasive and distant recurrence across all surrogate breast cancer subtypes in premenopausal patients with node-positive, hormone receptor-positive early breast cancer, with the greatest risk reduction observed in luminal A-like disease.
- Human trial 2026Dynamic Profiles of Serum Kisspeptin and DLK1 During GnRH Stimulation in Central Precocious Puberty and Premature Thelarche
This cross-sectional study found that dynamic changes in serum kisspeptin and DLK1 during GnRH stimulation differ between girls with central precocious puberty and premature thelarche, but diagnostic utility is limited due to considerable overlap.
- Human trial 2026Supplementary Material for: Dynamic Profiles of Serum Kisspeptin and DLK1 During GnRH Stimulation in Central Precocious Puberty and Premature Thelarche
This cross-sectional study examined dynamic serum kisspeptin and DLK1 levels during GnRH stimulation in girls with central precocious puberty and premature thelarche, finding distinct percentage changes at 60 minutes that may help differentiate the conditions but with uncertain diagnostic utility.
- Human trial 2026Supplementary Material for: Dynamic Profiles of Serum Kisspeptin and DLK1 During GnRH Stimulation in Central Precocious Puberty and Premature Thelarche
This study found that the dynamic responses of serum kisspeptin and DLK1 to GnRH stimulation differ between girls with central precocious puberty and premature thelarche, though their diagnostic utility remains uncertain.
+ 206 more studies indexed for Gonadorelin.
Frequently asked questions
- Is Gonadorelin approved for human use?
- Gonadorelin is a synthetic decapeptide identical to natural gonadotropin-releasing hormone (GnRH), which stimulates the pituitary to release LH and FSH. Its branded US products — Factrel (diagnostic use) and Lutrepulse (pulsatile pump therapy) — were FDA-approved but were voluntarily withdrawn from the market for commercial reasons, not safety or efficacy. As of 2026 no FDA-approved gonadorelin product is commercially available in the US; it is used off-label, mainly via compounding pharmacies, including as a testicular-function adjunct during testosterone therapy — an off-label use with no large randomised controlled trials.
- What does the research on Gonadorelin show?
- Gonadorelin's historical evidence base comes from the diagnostic and pulsatile-therapy trials that supported its former FDA approvals (Factrel for pituitary-gonadotroph function testing, Lutrepulse for pulsatile treatment of hypothalamic amenorrhoea). Those products were withdrawn from the US market in commercial decisions, not for safety reasons. Its current off-label use — preserving testicular function during testosterone replacement therapy — has not been evaluated in large randomised controlled trials; the evidence for that specific use is limited.